CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for Stakeholders
1.3. Key Market Segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key Findings
3.2.1. Top Winning Strategies
3.2.2. Top investment pockets
3.3. Key forces shaping LATAM women hypoactive sexual desire disorder treatment industry/market
3.4. Top player positioning, 2019
3.5. Annual Spending, 2019
3.6. Market dynamics
3.6.1. Drivers
3.6.1.1. Surge in prevalence of lifestyle ailments
3.6.1.2. Rise in use of medicines that induce hypoactive sexual desire disorder
3.6.1.3. The rise in the number of surgical procedures leading to sexual dysfunction
3.6.2. Restraint
3.6.2.1. Lack in awareness related to hypoactive sexual desire disorder
3.6.3. Opportunity
3.6.3.1. Presence of strong pipeline products
3.7. Impact Analysis
3.8. COVID-19 Impact Analysis on LATAM women hypoactive sexual desire disorder treatment market
3.9. Cognitive Behavior Therapy
3.9.1. Key market trends, growth factors, and opportunities
3.9.2. Market analysis, by country
CHAPTER 4: LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Buspirone
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market analysis, by country
4.3. Bupropion
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market analysis, by country
CHAPTER 5: LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL
5.1. Overview
5.1.1. Market size and forecast
5.2. Hospitals
5.2.1. Market analysis, by country
5.3. Clinics
5.3.1. Market analysis, by country
5.4. Online Retailers
5.4.1. Market analysis, by country
CHAPTER 6: LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY COUNTRY
6.1. Overview
6.1.1. Market size and forecast, by country
6.2. Brazil
6.2.1. Key market trends and growth opportunities
6.2.2. Brazil hypoactive sexual desire disorder (HSDD) treatment market, by treatment type
6.2.3. Brazil hypoactive sexual desire disorder (HSDD) treatment market, by sales channel
6.3. Argentina
6.3.1. Key market trends and growth opportunities
6.3.2. Argentina hypoactive sexual desire disorder (HSDD) treatment market, by treatment type
6.3.3. Argentina hypoactive sexual desire disorder (HSDD) treatment market, by sales channel
6.4. Chile
6.4.1. Key market trends and growth opportunities
6.4.2. Chile hypoactive sexual desire disorder (HSDD) treatment market, by treatment type
6.4.3. Chile hypoactive sexual desire disorder (HSDD) treatment market, by sales channel
6.5. Colombia
6.5.1. Key market trends and growth opportunities
6.5.2. Colombia hypoactive sexual desire disorder (HSDD) treatment market, by treatment type
6.5.3. Colombia hypoactive sexual desire disorder (HSDD) treatment market, by sales channel
6.6. Ecuador
6.6.1. Key market trends and growth opportunities
6.6.2. Ecuador hypoactive sexual desire disorder (HSDD) treatment market, by treatment type
6.6.3. Ecuador hypoactive sexual desire disorder (HSDD) treatment market, by sales channel
6.7. Peru
6.7.1. Key market trends and growth opportunities
6.7.2. Peru hypoactive sexual desire disorder (HSDD) treatment market, by treatment type
6.7.3. Peru hypoactive sexual desire disorder (HSDD) treatment market, by sales channel
6.8. Rest of LATAM
6.8.1. Key market trends and growth opportunities
6.8.2. Rest of LATAM women hypoactive sexual desire disorder (HSDD) treatment market, by treatment type
6.8.3. Rest of LATAM women hypoactive sexual desire disorder (HSDD) treatment market, by sales channel
CHAPTER 7: COMPANY PROFILES
7.1. AUROBINDO PHARMA
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance.
7.2. BRISTOL-MYERS SQUIBB COMPANY
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product Portfolio
7.2.5. Business performance
7.3. GLAXOSMITHKLINE PLC (GSK)
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance.
7.4. MYLAN N. V.
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.5. NOVARTIS INTERNATIONAL AG
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.6. PALATIN TECHNOLOGIES, INC.
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance.
7.6.6. Key strategic moves and developments
7.7. SPROUT PHARMACEUTicALS, INC.
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Key strategic moves and developments
7.8. SUN PHARMACEUTicAL INDUSTRIES LIMITED
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.9. TEVA PHARMACEUTicAL INDUSTRIES LTD. (ACTAVIS GENERicS)
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.10. ZYDUS CADILA
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance.
List of Tables
Table 01. Annual Spending on Women Hypoactive Sexual Desire Disorder (Hsdd) Treatment, by Country, 2019 (Us$)
Table 02. Latam Women Hypoactive Sexual Desire Disorder (Hsdd) Treatment Market for Cognitive Behavior Therapy, by Country, 2019-2027 ($Million)
Table 03. Latam Women Hypoactive Sexual Desire Disorder (Hsdd) Treatment Market for Cognitive Behavior Therapy, by Country, 2019-2027 (Number of Sessions)
Table 04. Latam Women Hypoactive Sexual Desire Disorder (Hsdd) Treatment Market, by Treatment Type, 2019-2027 ($Million)
Table 05. Latam Women Hypoactive Sexual Desire Disorder (Hsdd) Treatment Market, by Type, 2019-2027 (Million Units)
Table 06. Latam Women Hypoactive Sexual Desire Disorder (Hsdd) Treatment Market for Buspirone, by Country, 2019-2027 ($Million)
Table 07. Latam Women Hypoactive Sexual Desire Disorder (Hsdd) Treatment Market for Buspirone, by Country, 2019-2027 (Million Units)
Table 08. Latam Women Hypoactive Sexual Desire Disorder (Hsdd) Treatment Market for Bupropion, by Country, 2019-2027 ($Million)
Table 09. Latam Women Hypoactive Sexual Desire Disorder (Hsdd) Treatment Market for Bupropion, by Country, 2019-2027 (Million Units)
Table 10. Latam Women Hypoactive Sexual Desire Disorder (Hsdd) Treatment Market, by Sales Channel, 2019-2027 ($Million)
Table 11. Latam Women Hypoactive Sexual Desire Disorder (Hsdd) Treatment Market, by Sales Channel, 2019-2027 (Million Units)
Table 12. Latam Women Hypoactive Sexual Desire Disorder (Hsdd) Treatment Market for Hospitals, by Country, 2019-2027 ($Million)
Table 13. Latam Women Hypoactive Sexual Desire Disorder (Hsdd) Treatment Market for Hospitals, by Country, 2019-2027 (Million Units)
Table 14. Latam Women Hypoactive Sexual Desire Disorder (Hsdd) Treatment Market for Clinics, by Country, 2019-2027 ($Million)
Table 15. Latam Women Hypoactive Sexual Desire Disorder (Hsdd) Treatment Market for Clinics, by Country, 2019-2027 (Million Units)
Table 16. Latam Women Hypoactive Sexual Desire Disorder (Hsdd) Treatment Market for Online Retailers, by Country, 2019-2027 ($Million)
Table 17. Latam Women Hypoactive Sexual Desire Disorder (Hsdd) Treatment Market for Online Retailers, by Country, 2019-2027 (Million Units)
Table 18. Latam Women Hypoactive Sexual Desire Disorder (Hsdd) Treatment Market Revenue, by Country, 2019-2027 ($Million)
Table 19. Latam Women Hypoactive Sexual Desire Disorder (Hsdd) Treatment Market Revenue, by Country, 2019-2027 (Million Units)
Table 20. Brazil Hypoactive Sexual Desire Disorder (Hsdd) Treatment Market, by Treatment Type, 2019-2027 ($Million)
Table 21. Brazil Hypoactive Sexual Desire Disorder (Hsdd) Treatment Market, by Treatment Type, 2019-2027 (Million Units)
Table 22. Brazil Hypoactive Sexual Desire Disorder (Hsdd) Treatment Market, by Sales Channel, 2019-2027 ($Million)
Table 23. Brazil Hypoactive Sexual Desire Disorder (Hsdd) Treatment Market, by Sales Channel, 2019-2027 (Million Units)
Table 24. Argentina Hypoactive Sexual Desire Disorder (Hsdd) Treatment Market, by Treatment Type, 2019-2027 ($Million)
Table 25. Argentina Hypoactive Sexual Desire Disorder (Hsdd) Treatment Market, by Treatment Type, 2019-2027 (Million Units)
Table 26. Argentina Hypoactive Sexual Desire Disorder (Hsdd) Treatment Market, by Sales Channel, 2019-2027 ($Million)
Table 27. Argentina Hypoactive Sexual Desire Disorder (Hsdd) Treatment Market, by Sales Channel, 2019-2027 (Million Units)
Table 28. Chile Hypoactive Sexual Desire Disorder (Hsdd) Treatment Market, by Treatment Type, 2019-2027 ($Million)
Table 29. Chile Hypoactive Sexual Desire Disorder (Hsdd) Treatment Market, by Treatment Type, 2019-2027 (Million Units)
Table 30. Chile Hypoactive Sexual Desire Disorder (Hsdd) Treatment Market, by Sales Channel, 2019-2027 ($Million)
Table 31. Chile Hypoactive Sexual Desire Disorder (Hsdd) Treatment Market, by Sales Channel, 2019-2027 (Million Units)
Table 32. Colombia Hypoactive Sexual Desire Disorder (Hsdd) Treatment Market, by Treatment Type, 2019-2027 ($Million)
Table 33. Colombia Hypoactive Sexual Desire Disorder (Hsdd) Treatment Market, by Treatment Type, 2019-2027 (Million Units)
Table 34. Colombia Hypoactive Sexual Desire Disorder (Hsdd) Treatment Market, by Sales Channel, 2019-2027 ($Million)
Table 35. Colombia Hypoactive Sexual Desire Disorder (Hsdd) Treatment Market, by Sales Channel, 2019-2027 (Million Units)
Table 36. Ecuador Hypoactive Sexual Desire Disorder (Hsdd) Treatment Market, by Treatment Type, 2019-2027 ($Million)
Table 37. Ecuador Hypoactive Sexual Desire Disorder (Hsdd) Treatment Market, by Treatment Type, 2019-2027 (Million Units)
Table 38. Ecuador Hypoactive Sexual Desire Disorder (Hsdd) Treatment Market, by Sales Channel, 2019-2027 ($Million)
Table 39. Ecuador Hypoactive Sexual Desire Disorder (Hsdd) Treatment Market, by Sales Channel, 2019-2027 (Million Units)
Table 40. Peru Hypoactive Sexual Desire Disorder (Hsdd) Treatment Market, by Treatment Type, 2019-2027 ($Million)
Table 41. Peru Hypoactive Sexual Desire Disorder (Hsdd) Treatment Market, by Treatment Type, 2019-2027 (Million Units)
Table 42. Ecuador Hypoactive Sexual Desire Disorder (Hsdd) Treatment Market, by Sales Channel, 2019-2027 ($Million)
Table 43. Peru Hypoactive Sexual Desire Disorder (Hsdd) Treatment Market, by Sales Channel, 2019-2027 (Million Units)
Table 44. Rest of Latam Women Hypoactive Sexual Desire Disorder (Hsdd) Treatment Market, by Treatment Type, 2019-2027 ($Million)
Table 45. Rest of Latam Women Hypoactive Sexual Desire Disorder (Hsdd) Treatment Market, by Treatment Type, 2019-2027 (Million Units)
Table 46. Rest of Latam Women Hypoactive Sexual Desire Disorder (Hsdd) Treatment Market, by Sales Channel, 2019-2027 ($Million)
Table 47. Rest of Latam Women Hypoactive Sexual Desire Disorder (Hsdd) Treatment Market, by Sales Channel, 2019-2027 (Million Units)
Table 48. Aurobindo: Company Snapshot
Table 49. Aurobindo: Product Portfolio
Table 50. Bms: Company Snapshot
Table 51. Bms: Product Portfolio
Table 52. Gsk: Company Snapshot
Table 53. Gsk: Operating Segments
Table 54. Gsk: Product Portfolio
Table 55. Mylan: Company Snapshot
Table 56. Mylan: Operating Business Segments
Table 57. Mylan: Product Portfolio
Table 58. Novartis: Company Snapshot
Table 59. Novartis: Operating Segments
Table 60. Novartis: Product Portfolio
Table 61. Palatin: Company Snapshot
Table 62. Palatin: Product Portfolio
Table 63. Sprout: Company Snapshot
Table 64. Sprout: Operating Segments
Table 65. Sprout: Product Portfolio
Table 66. Sprout: Key Strategic Moves and Developments
Table 67. Sun Pharma: Company Snapshot
Table 68. Sun Pharma: Operating Segments
Table 69. Sun Pharma: Product Portfolio
Table 70. Teva: Company Snapshot
Table 71. Teva: Operating Segments
Table 72. Teva: Product Portfolio
Table 73. Zydus: Company Snapshot
Table 74. Zydus: Operating Segments
Table 75. Zydus: Product Portfolio
List of Figures
Figure 01. Latam Women Hypoactive Sexual Desire Disorder Treatment Market Segmentation:
Figure 02. Top Investment Pockets
Figure 03. Moderate Bargaining Power of Supplier
Figure 04. Low Bargaining Power of Buyers
Figure 05. Low Threat of Substitutes
Figure 06. High Intensity of Rivalry
Figure 07. Moderate Threat of New Entrant
Figure 08. Top Player Positioning, 2019
Figure 09. Impact Analysis, Latam Women Hypoactive Sexual Desire Disorder Treatment Market
Figure 10. Aurobindo: Net Sales, 2018-2020 ($Million)
Figure 11. Aurobindo: Revenue Share, by Region, 2020 (%)
Figure 12. Bms: Net Sales, 2017-2019 ($Million)
Figure 13. Bms: Revenue Share, by Region, 2019 (%)
Figure 14. Gsk: Net Sales, 2017-2019 ($Million)
Figure 15. Gsk: Revenue Share, by Segment, 2019 (%)
Figure 16. Gsk: Revenue Share, by Region, 2019 (%)
Figure 17. Mylan: Net Sales, 2017-2019 ($Million)
Figure 18. Mylan: Revenue Share, by Region, 2019 (%)
Figure 19. Novartis: Net Sales, 2017-2019 ($Million)
Figure 20. Novartis: Revenue Share, by Segment, 2019 (%)
Figure 21. Novartis: Revenue Share, by Region, 2019 (%)
Figure 22. Palatin: Net Sales, 2018-2020 ($Million)
Figure 23. Sun Pharma: Net Sales, 2018-2020 ($Million)
Figure 24. Sun Pharma: Revenue Share, by Segment, 2020 (%)
Figure 25. Sun Pharma: Revenue Share, by Geography, 2020 (%)
Figure 26. Teva: Net Sales, 2017-2019 ($Million)
Figure 27. Teva: Revenue Share, by Segment, 2019 (%)
Figure 28. Teva: Revenue Share, by Region, 2019 (%)
Figure 29. Zydus: Net Sales, 2018-2020 ($Million)
Figure 30. Zydus: Revenue Share, by Segment, 2020 (%)
Figure 31. Zydus: Revenue Share, by Region, 2020 (%)